Antibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 17758-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#17758-1-AP, RRID:AB_2261476
- Product name
- DCK antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated DCK antibody (Cat. #17758-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: WB,ELISA.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references m6A Methyltransferase METTL14-Mediated Upregulation of Cytidine Deaminase Promoting Gemcitabine Resistance in Pancreatic Cancer.
KNSTRN promotes tumorigenesis and gemcitabine resistance by activating AKT in bladder cancer.
Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma.
Abrogation of ARF6 promotes RSL3-induced ferroptosis and mitigates gemcitabine resistance in pancreatic cancer cells.
Using RNA-seq and targeted nucleases to identify mechanisms of drug resistance in acute myeloid leukemia.
Zhang C, Ou S, Zhou Y, Liu P, Zhang P, Li Z, Xu R, Li Y
Frontiers in oncology 2021;11:696371
Frontiers in oncology 2021;11:696371
KNSTRN promotes tumorigenesis and gemcitabine resistance by activating AKT in bladder cancer.
Xiong Y, Ju L, Yuan L, Chen L, Wang G, Xu H, Peng T, Luo Y, Xiao Y, Wang X
Oncogene 2021 Mar;40(9):1595-1608
Oncogene 2021 Mar;40(9):1595-1608
Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma.
Dell'Anno I, Martin SA, Barbarino M, Melani A, Silvestri R, Bottaro M, Paolicchi E, Corrado A, Cipollini M, Melaiu O, Giordano A, Luzzi L, Gemignani F, Landi S
Investigational new drugs 2021 Jun;39(3):644-657
Investigational new drugs 2021 Jun;39(3):644-657
Abrogation of ARF6 promotes RSL3-induced ferroptosis and mitigates gemcitabine resistance in pancreatic cancer cells.
Ye Z, Hu Q, Zhuo Q, Zhu Y, Fan G, Liu M, Sun Q, Zhang Z, Liu W, Xu W, Ji S, Yu X, Xu X, Qin Y
American journal of cancer research 2020;10(4):1182-1193
American journal of cancer research 2020;10(4):1182-1193
Using RNA-seq and targeted nucleases to identify mechanisms of drug resistance in acute myeloid leukemia.
Rathe SK, Moriarity BS, Stoltenberg CB, Kurata M, Aumann NK, Rahrmann EP, Bailey NJ, Melrose EG, Beckmann DA, Liska CR, Largaespada DA
Scientific reports 2014 Aug 13;4:6048
Scientific reports 2014 Aug 13;4:6048
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The DCK antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human DCK. This antibody recognizes human,mouse,rat antigen. The DCK antibody has been validated for the following applications: ELISA, WB analysis.